Literature DB >> 15834541

[Blood pressure and the brain].

A Hartmann1, S Moskau.   

Abstract

During acute cerebral infarction, autoregulation is abolished. Brain perfusion therefore directly depends on perfusion pressure and cardiac output. For this reason, in the early state of stroke, elevated blood pressure improves cerebral blood flow and only values of 210 mmHg systolic or above should be lowered. With the development of a vasogenic brain edema or a dysfunctional blood-brain barrier (usually on day 2 to 4 after infarction), blood pressure must be normalized in order to avoid hemorrhage and to minimize edema. In the presence of space occupying edema or intracranial hemorrhage, only those antihypertensive substances may be used which do not cause a dilatation of brain vessels. Direct vasodilators and calcium antagonists are not suitable in this situation. Furthermore, antihypertensive medication which causes bradycardia (e.g. beta blockers) should be avoided, because in acute stroke, brain perfusion also depends on the cardiac output. For primary and secondary stroke prevention normalization of blood pressure is essential. Efficacy is basically independent of the kind of antihypertensive medication used. Effective normalization of blood pressure probably helps to prevent vascular dementias of all kinds. Convincing studies however are still lacking for most sorts of antihypertensive medication.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15834541     DOI: 10.1007/s00108-005-1406-9

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  135 in total

1.  Surveillance of stroke: a global perspective.

Authors:  T Truelsen; R Bonita; K Jamrozik
Journal:  Int J Epidemiol       Date:  2001-10       Impact factor: 7.196

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

3.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

Authors:  J A Staessen; R Fagard; L Thijs; H Celis; G G Arabidze; W H Birkenhäger; C J Bulpitt; P W de Leeuw; C T Dollery; A E Fletcher; F Forette; G Leonetti; C Nachev; E T O'Brien; J Rosenfeld; J L Rodicio; J Tuomilehto; A Zanchetti
Journal:  Lancet       Date:  1997-09-13       Impact factor: 79.321

Review 4.  Triggers, acute risk factors and vulnerable plaques: the lexicon of a new frontier.

Authors:  J E Muller; G S Abela; R W Nesto; G H Tofler
Journal:  J Am Coll Cardiol       Date:  1994-03-01       Impact factor: 24.094

5.  Blood pressure and clinical outcomes in the International Stroke Trial.

Authors:  Jo Leonardi-Bee; Philip M W Bath; Stephen J Phillips; Peter A G Sandercock
Journal:  Stroke       Date:  2002-05       Impact factor: 7.914

6.  Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.

Authors:  Henry R Black; William J Elliott; Gregory Grandits; Patricia Grambsch; Tracy Lucente; William B White; James D Neaton; Richard H Grimm; Lennart Hansson; Yves Lacourciere; James Muller; Peter Sleight; Michael A Weber; Gordon Williams; Janet Wittes; Alberto Zanchetti; Robert J Anders
Journal:  JAMA       Date:  2003 Apr 23-30       Impact factor: 56.272

7.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

8.  Lowering of blood pressure after stroke.

Authors:  H F Loyke
Journal:  Am J Med Sci       Date:  1983 Sep-Oct       Impact factor: 2.378

9.  Hemodynamic response to intravenous enalaprilat in patients with severe congestive heart failure and mitral regurgitation.

Authors:  P Varriale; W David; B E Chryssos
Journal:  Clin Cardiol       Date:  1993-03       Impact factor: 2.882

Review 10.  Blood pressure, antihypertensive treatment and stroke risk.

Authors:  S MacMahon; A Rodgers
Journal:  J Hypertens Suppl       Date:  1994-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.